IDEAYA Biosciences, Inc.
IDYA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $2 | $1 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $2 | $1 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | 99.5% | – | – | 90.8% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 57.9% | – | – | -1,852.4% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 57.4% | – | – | -1,861.6% |
| EPS Diluted | 1.33 | -0.88 | -0.82 | -1.49 |
| % Growth | 251.1% | -7.3% | 45% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |